Ayurvedic formulations: Potential COVID-19 therapeutics?

Abstract

Background: While Molnupiravir and Paxlovid have recently been approved for use in some countries, there are no widely available treatments for COVID-19, the disease caused by SARS-CoV-2 infection. Herbal extracts have been used to treat respiratory clinical indications by Ayurvedic medicine practitioners with minimal adverse reactions and intense research efforts are currently under way to develop some of these formulations for COVID-19 treatment.

Methods: Literature search for in silico, in vitro, in vivo, and clinical studies on the topic of Ayurvedic formulations for potential COVID-19 treatment, in order to present the current state of current knowledge by integrating information across all systems.

Results: The search yielded 20 peer reviewed articles on in silico studies examining the interaction of phytoconstituents of popular Ayurvedic formulations with SARS-CoV-2 components and its receptors; five articles on preclinical investigations of the ability of selected Ayurvedic formulations to inhibit functions of SARS-CoV-2 proteins; and 51 completed clinical trials on the efficacy of using Ayurvedic formulations for treatment of mild to moderate COVID-19. Clinical data was available from 17 of the 51 trials. There was a considerable overlap between formulations used in the in silico studies and the clinical trials. This finding was unexpected as there is no clearly stated alignment between studies and the traditional pathway to drug discovery– basic discovery leading to in vitro and in vivo proof of concept, followed by validation in clinical trials. This was further demonstrated in the majority of the in silico studies where focus was on potential antiviral mechanisms, while the clinical trials were focused on patient recovery using oral treatments. In all 17 clinical trials where data was available, Ayurvedic treatments lead to a shorter period to recovery in participants with COVID-19.

Conclusion: The most commonly used Ayurvedic treatments for management of respiratory symptoms associated with SARS-CoV-2 infection appear to have prophylactic and/or therapeutic properties. It would be of particular interest to assess synergistic and concomitant systemic effects and antiviral activities of individual phytoconstituents and their combinations in the Ayurvedic treatments.

Graphical abstract

Abbreviations

3CL^pro

3C like protease

M^pro

Main protease

ACE2

angiotensin converting enzyme 2

COVID-19

coronavirus infectious disease 2019

ERGIC

endoplasmic reticulum Golgi intermediate compartment

KSK

Kabasura Kudineer

(MERS)-CoV

Middle Eastern Respiratory Syndrome

NSP

nonstructural protein

NVK

Nilavembu Kudineer

RBD

receptor binding domain

SARS-CoV

Severe Acute Respiratory Syndrome coronavirus

TMPRSS2

transmembrane serine protease 2

uHPLCPDA

an ultra-high-performance liquid chromatographic-photodiode array

vRNP

viral ribonucleoprotein

Introduction

Human coronaviruses usually cause common cold symptoms, except for the recently emerged betacoronaviruses, including Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), Middle Eastern Respiratory Syndrome (MERS)-CoV (Fung and Liu, 2019) and SARS-CoV-2 that can cause severe disease and in extreme cases, death (WHO, 2021a). The SARS-CoV-2, identified as the causative agent for COVID-19 and the current pandemic, emerged in 2019 and has rapidly spread around the world, evolving into highly transmissible strains, the delta and omicron variants and recent subvariants (WHO, 2021a). Individuals infected with COVID-19 present with a range of clinical manifestations, from asymptomatic to mild (cough, chest pain, loss of taste, back pain) to fatal (death). There have been over 464 million confirmed cases and more than 6 million deaths worldwide (WHO, 2021b) (information current as of 20 March 2022), with a concerted effort around the world to develop and deploy vaccines for protection from emerging SARS-CoV-2 strains. Although several vaccines have been approved for use in adult, adolescent and older children populations (March 2022), no vaccine has been approved for infants and young children below the age of 5 years. It is envisaged that once the majority of the global eligible population has been vaccinated, the younger, currently ineligible, population will be at a high risk of infections. Access to safe and effective therapeutics would greatly enhance our ability to manage SARS-CoV-2 infections into the future.

Currently, there are no widely available therapeutics for the management of COVID-19 (Siemieniuk et al., 2020), however, recent clinical trial data from several drug treatment options are showing promising results. Fluvoxamine (Abbott Laboratories) has shown good results in treating COVID-19 by preventing patients from developing serious illness and reducing the risk of hospitalization (Reis et al., 2022), while Novartis has declared topline data from their Phase 2 study for Ensovibep showing viral load reduction over eight days. Pfizer has announced promising outcomes from clinical trials of Paxlovid™ that targets the SARS-CoV-2 3C-like protease, while Merck has announced similar results from trials of Molnupiravir, a nucleoside analog (Drozdzal et al., 2021; Jayk Bernal et al., 2021). The latter two experimental drugs have been authorized by the FDA and are approved for use in several countries.

The use of nutraceuticals and/or dietary supplements, including herbal medicines, is well established for the management of several respiratory indications (Chan et al., 2021; Chen et al., 2014) and the interest in their antiviral properties has also been investigated in the context of the current COVID-19 pandemic (Parisi et al., 2021; Singh et al., 2021; Steel et al., 2020). Many research groups have examined the potential use of natural products and substances already available for use for other indications, such as Ayurvedic formulations that are widely used in India and within the Indian diaspora (Ayatollahi et al., 2021). Ayurveda is an ancient Indian holistic system of medicine that utilizes plant extracts as one of the main ingredients for their formulations (National Center for Complementary and Integrative Health,  2022). Given the widespread use of Ayurvedic formulations as complementary medicine, they provide an attractive avenue for development of anti-COVID-19 treatments that would be safe and well tolerated (Singh et al., 2018; Steel et al., 2020).

In this review we aim to summarize the current literature on the efficacy of natural compounds most commonly used in Ayurvedic formulations with potential anti-SARS-CoV-2 properties, in order to gage the current stage of knowledge in this topic and provide the stepping-stone for development of successful anti-viral treatments.

SARS-CoV-2

The main structural components of coronaviruses are the spike glycoprotein S, the transmembrane proteins M (membrane) and E (envelope), and the nucleoprotein N. The S, M and E proteins are embedded in the virus envelope while N protein forms a viral ribonucleoprotein (vRNP) complex with the viral RNA (V'Kovski et al., 2021). The SARS-CoV-2 genome is organized similarly to other coronaviruses and the positive-stranded RNA genome has a 5′-cap and a 3′-poly-A tail, allowing its translation from the host translation machinery. A frameshift between two open reading frames (Orf), Orf1a and Orf1b at the 5′-end of the genome allows production of two polypeptides that are then proteolytically processed to produce 16 non-structural proteins (Nsp1–16) that are involved in various processes of the virus infection cycle. The structural S, N, M and E proteins are encoded at the 3′-end. The life cycle of SARS-CoV-2 involves the initial infection of human cells through the host cell receptor angiotensin-converting enzyme 2 (ACE2), together with the cell surface serine protease TMPRSS2 that acts as a coreceptor mediated by the S glycoprotein via its receptor binding domain (RBD). Following entry via endocytosis, the positive-sense RNA genome is translated into a polyprotein with RNA polymerase function; this produces negative-sense sub-genomic mRNA before making positive-sense sub-genomic mRNA ready for translation. Following translation, the components associate in the endoplasmic reticulum Golgi intermediate compartment (ERGIC) before being released by exocytosis. We would like to direct the reader to excellent articles on the structure and life cycle of SARS-CoV-2 and its relationship to other known coronaviruses (V'Kovski et al., 2021; Yang and Rao, 2021) as these aspects will not be discussed in detail in this manuscript. Most of the antiviral development efforts against SARS-CoV-2 have targeted the glycoprotein S which is the major receptor binding protein. This glycoprotein is also the focus of the vaccine development efforts as it is the main target of our immune response. As the coronavirus 3C-like protease 3CL^pro (also termed M^pro) is critical for virus polyprotein processing and virus replication this enzyme poses as another viable antiviral target.

Search strategy

The main motivation for this review was to understand how Ayurvedic formulations can support the clinical management of individuals infected with COVID-19. Our search strategy involved five electronic databases: Scopus, PubMed, AYUSH Research Portal, Clinical Trial Registry-India (CTRI), and ClinicalTrials.gov since the journals and websites inception until 22 October 2021. We have also performed updated searches for any additional articles that may be of interest just prior to re-submission of this manuscript (20 March 2022). The keywords used included “SARS-CoV-2” AND/OR “COVID-19” AND “Ayurveda”. The resulting database of research literature and clinical trials included in silico studies, pre-clinical laboratory studies and clinical trials published in English. Clinical trials where no trial data was available were excluded. The various Ayurvedic formulations mentioned in this review and their herbal constituents are listed in Table 1 .

Table 1.

Herbal constituents of Ayurvedic formulations referred to in the text.

Ayurvedic name	Constituents
Adathodai Manapagu	Adhatoda vasica
Agnikumara Rasa	Piper nigrum
Amalaki Churna	Phyllanthus emblica
Amruth	Tinospora cordifolia
Amrutha Sanjeevini	Tinospora cordifolia, Phyllanthus emblica, Ocimum tenuiflorum, Andrographis paniculate, Glycyrrhiza glabra, Withania somnifera
Amukkara	Withania somnifera, Zingiber officinale, Piper nigrum, Piper longum, Elettaria cardamomum, Cinnamomum verum, Syzygium aromaticum, Saccharum officinaru, Messua ferrea.
Anu Taila	Herbal oil with >20 ingredients*, including Ocimum tenuiflorum, Elettaria cardamomum, Cinnamomum zeylancium.
Arogya Kashayam-20	Tinospora cordifolia, Zingiber officinale, Phyllanthus niruri, Glycyrrhiza glabra, Terminalia chebula, Piper longum, Piper nigrum.
AyurCoro-3	Seven ingredients, including Curcuma longa.
AYUSH 64	Alstonia cholaris, Picrorhiza kurroa, Swertia chirata, Caesalpinia crista
Bilvadi	Seven herbs and spices, including Zingiber officinale, Coriandrum sativum, Piper longum, Piper nigrum, Aegle marmelos.
Brahmananda Bhairavam	Zingiber officinale
Bresol	11 ingredients, including Curcuma longa, Ocimum Sativum, Adathoda vasica, Zingiber Officinale.
CIM-MEG19	Andrographis paniculata
CLEVIRA	ten ingredients, including Tinospora cordifolia and Andrographis paniculata
CONTAZAP	Andrographis panniculata, Rheum emodi, Embelica officinalis.
Dashamula Kwatha	Aegle marmelos, Premna mucronate, Oroxylum indicum, Stereospermem suaveolens, Gmelina afborea, Solanum indicum, Solanum xanthocarpum, Tribulus terrestris, Desmodium gangeticum, Uraria picta
Giloy	Tinospora cordifolia
Golden Milk, Ojovardhini	Curcuma longa
Immunofree	14 ingredients, including Andrographis paniculata, Phylanthus niruri, Glycirhizza glabra, Ocimum tenuiflorum, Tinospora cordifolia, Curcuma longa.
Immuzan	Ocimum tenuiflorum, Curcuma longa, Embelica officinalis, Zingiber officinale
Jeevaneeyam	15 ingredients, including Tinospora cordifolia, Phyllanthus emblica, Ocimum tenuiflorum, Glycyrrhiza glabra
Kalmegh	Andrographis paniculata
Kantakaryavaleha	14 ingredients, including Tinospora cordifolia, Piper longum, Piper nigrum, Zingiber officinale.
Mahasudarsan Chooranam	Polyherbal with >50 herbal ingredients.
Maldevi Chendooram	not a herbal
Nagaradi kwath	Zingiber officinale, Terminalia chebula, Tinospora cordifolia,
Nochi Kudineer Chooranam	Vitex negundo, Artemisia pallens, Piper nigrum, Allium sativum, Piper betle.
NOQ19	19 ingredients, including Withania somnifera, Aegle marmelos, Glycyrrhiza glabra Pluchea lanceolata, Adhatoda vasica, Piper longum, Curcuma longa, Cissampelos pareira, Phyllanthus fraternus, Andrographis paniculate, Alstonia scholaris, Ocimum tenuiflorum, Tinospora cordifolia.
Oma theeneeer	Trachispermum roxburghianum
Pathyadi Kwatha	Terminalia chebula, Terminalia bellirica, Emblica officinalis, Andrographis paniculate, Curcuma longa, Azadireachta indica, Tinospora cordifolia.
PINAK	Erythrina indica, Magnefera indica, Eugenia jambolana, Jusminum sambac
Pipli	Piper longum
Rasona	Allium sativum
Reginmune	Echinacea purpurea, Aloe vera, Uncaria tomentosa
Sanshamani Vati	Tinospora cordifolia
Septilin	∼35 ingredients, including Commiphora wightii, Tinospora cordifolia, Phyllanthus emblica, Glycyrrhiza glabra
Shadangodak	Cyperus rotundus, Fumaria indica, Vetiveria zizanioides, Santalum album, Andropogan vetiveria, Zingiber officinale
Shakthi	Emblica officinalis, Withania somnifera, monnieri, Eclipta alba, Tinospora cordifolia, Asparagus racemosus, Convolvulus pluricaulis, Glycyrrhiza glabra. Bacopa
Shunthi	Zingiber officinale
SSV Formulation	Curcuma longa and other ingredients
Surasadi Kadha	Ocimum tenuiflorum, Solanum virginianum, Tinospora cordifolia, Zingiber officinale, Curcuma longa, Adathoda vasica, Elettaria cardamomum, Piper nigrum, Piper longum, Acorus calamus.
Swasari Ras	10 ingredients, including Glycyrrhiza glabra, Syzygium aromaticum, Cinnamomum zeylancium, Pistacia chinensis, Capparis noonii, Zingiber officinale, Piper longum.
T-AYU-HM Premium	11 ingredients, including Terminala chebula, Zingiber officinale, Punica granatum, Asparagus racemosus, Piper longum, Myristica fragrans, Leptadinia reticlata and Tinospora cordifolia.
Thaleesadhivadagam	14 ingredients, including Piper nigrum, Piper longum, Zingiber officinale, Elettaria cardamomum
Trikatu Churna	Zingiber officinale, Piper longum, Piper nigrum.
Trishun	Proprietary formulation with >50 ingredients.
ViroNil	Tinospora cordifolia, Ocimum tenuiflorum, Zingiber officinale, Curcuma longa, Piper nigrum, Phyllanthus emblica including others.
Vyaghryadi Kashaya	Solanum xanthocarpum, Zingiber officinalis, Tinospora cordifolia, Piper longum
Yastimadhu Ghanavati	Glycyrrhiza glabra

*other constituents are non-herbal and may include minerals.

In silico investigations

The searches have identified 20 peer reviewed publications of studies utilizing in silico techniques to determine the possible direct antiviral effect of known phytoconstituents of Ayurvedic formulations. The Ayurvedic formulations were composed of natural extracts from multiple plant sources, therefore, it is essential to understand the possible antiviral effect of the phytoconstituents and their metabolites within the extracts. Among various antiviral activities exhibited by plant metabolites, angiotensin converting enzyme 2 (ACE2) inhibitors have been explored in detail and shown to be a possible way to manage SARS-CoV-2 infection (V'Kovski et al., 2021). Ayurvedic formulations have also been studied for their potential inhibition of M^pro activity (Gurung et al., 2020; Havranek and Islam, 2021). Although there are relatively limited studies examining the potential of Ayurvedic formulations to inhibit RNA polymerase activity, these formulations may present excellent candidates for development as RNA polymerase inhibitors as they are usually less toxic than other antiviral strategies (Antonio et al., 2020). The most common targets of the phytoconstituents studied are the S protein, ACE2 receptor, TMPRSS2 (SARS-CoV-2 co-receptor) and M^pro (Fig. 1 ).

Fig. 1.

Common phytoconstituents of Ayurvedic formulations and their targets.

A summary of the results of the in silico studies reviewed is provided. The most common targets of the phytoconstituents studied are shown in the central quardants, while the phytoconstituents are listed in the associated rectangles. The size of the rectangles is relative to the number of compounds.

One of the most popular Ayurvedic therapies currently used for treatment of COVID-19 (asymptomatic, mild to moderate) in India, particularly in the state of Tamil Nadu, is the “Kabasura Kudineer” (KSK), a polyherbal formulation containing over 32 plant metabolites that is generally used to treat other respiratory symptoms (Jeyanthi and Kumar, 2020; Kiran et al., 2020; Rao et al., 2020). The KSK constituents include Magnoflorine, scutellarein, chrysoeriol, 5‑hydroxy-7,8 dimethoxyflavanone, tinosponone, cirsimaritin, chrysoeriol, 6- methoxygenkwanin, vasicinone, quercetin and luteolin, obtained from Sida acuta, Andrographis paniculata, Tinospora cordifolia, Plectranthus amboinicus, Justicia adhatoda,and Costus speciosus. All of these were found to have excellent predicted binding affinity with the SARS-CoV-2 S protein (Kiran et al., 2020). The molecular dynamics simulation showed that scutellarein, chrysoeriol, luteolin, cirsimaritin, and magnoflorine have strong affinity towards the spike protein via hydrogen bond contact with amino acids Arg 346, Asn343, Asp364, Cys336, Gly339, Ser373, Thr345, and Val341. The same research group have also found that phytoconstituents vasicine (quinazoline alkaloid), andrographolide (labdane diterpenoid), ursolic acid (pentacyclic triterpenoid acid), quercetin (flavonol) and meliacine (peptide) were predicted to inhibit the ACE2 receptor (Kiran et al., 2020). “Nilavembu Kudineer” (NVK), an Ayurvedic formulation containing nine herbal ingredients, is commonly used to treat respiratory illnesses due to its anti-inflammatory, anti-analgesic, and anti-pyretic effects. One of the most predominant phytoconstituents of NVK is andrographolide, derived from the herb A. paniculata that is used for supporting the immune function and relieve symptoms of the common cold. The findings of in silico studies have indicated that andrographolide can dock successfully in the binding site of SARS-CoV-2 M^pro (free energy −3.094 kJ/mol) and shows further promise in potential therapeutic use due to its relatively high solubility and favourable pharmacodynamics characteristics (Enmozhi et al., 2021). The relevant chemical structures are shown in Fig. 2 .

Fig. 2.

Structure of common phytoconstituents of Ayurvedic formulations.

Chemical structures of compounds, arranged by the target binding proteing, are shown. Compounds that bind to SARS-CoV-2 spike (S) protein (A), large protease Mpro (B), nucleocapsid (N) protein (C), Nonstructural protein Nsp15 (D), Nsp9 (E) are shown. Compounds that bind to ACE2 receptor are shown in (G). Compounds that bind to more than one relevant target are shown in F, H, I, J, K, L, M. TMPRSS2 is a co-receptor for SARS-CoV-2.

T. cordifolia, a common constituent of several different Ayurvedic formulations, including KSK and NVK, has received considerable attention for its potential anti-SARS-CoV-2 properties. The aqueous extract of T. cordifolia, known as “Guduchi Ghan Vati” or “Shilajatu Rasayana”, is used widely in Ayurvedic medicine management of several health conditions (Upadhyay et al., 2010). An in silico molecular docking study found that its phytoconstituents including berberine (alkaloid), isocolumbin (diterpenoid), magnoflorine (quaternary benzylisoquinoline), and tinocordiside (sesquiterpene glycoside) could potentially bind with high efficiency to the S glycoprotein in its prefusion state and to the receptor binding-domain of the mature S glycoprotein (Sagar and Kumar, 2021). These phytoconstituents may also provide preventative measures for COVID-19 by inhibiting the attachment of the virus to its host cells as evidenced by the low IC₅₀ (<1 μM) of tinocordiside and isocolumbin. A study by Mulpuru and Mishra (2021) found that of all T. cordiflora phytoconstituents investigated, saponarin (flavone glucoside) showed the highest affinity for docking with SARS-CoV-2 M^pro, with affinity ($-$8.75 kCal/ml) exceeding that of a nucleotide prodrug of an adenosine analog, Remdesivir (Mulpuru and Mishra, 2021). Remdesivir has been shown to shorten the time of recovery of individuals hospitalized with COVID-19 and evidence of lower respiratory tract infections (Beigel et al., 2020). Additionally, molecular dynamics simulation showed that saponarin-M^pro interaction was stable, without any significant fluctuations. In another in silico molecular docking and dynamics study, two bioactive constituents of T. cordiflora, amritoside (tannin) and apigenin-6-C-glucosyl-7-O-glucoside, were predicted to bind to the M^pro with high affinity, $-$60.35 and $-$50.50 kCal/mol respectively (Murugesan et al., 2021). In the same study, pectolinarin (cirsium isolate), a bioactive compound found in extracts of Phyllanthus niruri, as well as astragalin (3-O-glucoside of kaempferol) and quercetin, bioactive constituents of Emblica officinalis extracts, were also found to efficiently occupy the substrate binding cleft of M^pro in silico. P. niruri and E. officinalis are used in Ayurvedic medicine as components of several formulations and on their own as extracts for various conditions.

The “Ayurvedic Rasayana” describes a group of herbs used as dietary supplements that are proposed to exhibit immunomodulatory and antioxidant activities with extracts of T. cordifolia, Withania somnifera, and Asparagus racemosus major constituents of Rasayana therapy. A study by Borse et al. (2021) used an ultra-high-performance liquid chromatographic-photodiode array (uHPLC-PDA) and identified 31 phytoconstituents in the combined extract (Borse et al., 2021). All 31 phytoconstituents were tested for their immunomodulatory potential using an in silico network pharmacology model, followed by in silico molecular docking investigations with the SARS-CoV-2 S, M^pro and polymerase proteins. Network analysis showed that 53 protein targets in 28 of the 31 phytoconstituents were involved in 20 immune pathways, suggesting that the extract could concomitantly modulate multiple immune pathways. Two phytoconstituents, ashwagandhanolide (dimeric withanolide; Fig. 2A) and withacoagin, had high docking scores of $-$10 and $-$7.6 kCal/mol respectively, for SARS-CoV-2 S protein, forming strong hydrogen bond interactions with Arg403, Asn501, Ser494, Thr500, and Tyr495. However, the authors raised concerns about their drug-likeness as determined by the Lipinski's rule of five (Borse et al., 2021).

A literature review on the use of withanolides (phytoconstituents of W. somnifera) in COVID-19 (Dhawan et al., 2021) indicated that withanolides inhibit the ACE2 mediated entry of SARS-CoV-2 into host cells and subsequent M^pro activity. There was no direct evidence provided of either action with most of the molecular docking studies included. The authors proposed that withanone, withanolide D, withanolide A, and withaferin A have the potential to alter M^pro activity, while withanoside II, withanoside IV, withanoside V, sitoindoside IX, withanolide R and 2,3‐dihydrowithaferin A interfere with M^pro action (Dhawan et al., 2021; Kumar et al., 2020c; Parida et al., 2020; Tripathi et al., 2021). Interestingly, withanone and withaferin A (Fig. 2K–M) were also predicted to bind and stably interact at the catalytic site of TMPRSS2, the SARS-CoV-2 co-receptor, inducing changes at the allosteric site, which would potentially inhibit virus entry into host cells (Kumar et al., 2020c). Withanoside X and quercetin glucoside (Fig. 2D) may bind to the active site of NSP15 endoribonuclease and S protein RBD (Chikhale et al., 2021). A 100 ns molecular dynamics simulation suggests that withanoside X has high binding affinity with free energy value of $-$89.42 kCal/mol. Withaferin A, withanolide A, withanolide B, and withanone also have excellent predicted binding affinity to S protein, ACE2 receptor, and M^pro (Srivastava et al., 2020). Additionally, molecular dynamics simulation suggested that withanolides A and B bind stably to the S protein and the papain-like protease (PLpro) of SARS-CoV-2.

A survey of 17 bioactive phytoconstituents of commonly used herbs in Ayurveda for management of fever, inflammation and immune disorders, found that curcumin, nimbin, withaferin A, piperine, mangiferin, thebaine, berberine, and andrographolide have favourable drug-likeness characteristics and may effectively inhibit the interaction of SARS-CoV-2 S protein with its receptor (Maurya et al., 2020b). Nimbin and curcumin had very high docking scores of $-$148.621 kCal/mol and $-$141.36 kCal/mol respectively, comparable to the results for the antiviral nafamostat and hydroxychloroquine. Both nimbin and curcumin were predicted to interact via hydrogen bonding with S protein amino acid residues Arg 765, Asn317, Gln314, Lys304, Thr768, and Ser316. In a study by Maurya et al. (2020a), 20 phytoconstituents from herbs commonly used in Ayurveda, Allium cepa, Allium sativum, Alstonia scholaris, Artemisia vulgaris, Atropa belladonna, Caesalpinia crista, Glycyrrhiza glabra, Nigella sativa, Picrorhiza kurroa, Piper nigrum, Swertia chirata, T. cordifolia and Zingiber officinale were investigated for their ability to bind to the SARS-CoV-2 S protein and its ACE2 receptor (Maurya et al., 2020a). Computational structure-based drug design revealed that the compounds amarogentin, eufoliatorin, α-amyrin, caesalpinins, kutkin, β-sitosterol, and belladonnine have potentially high affinity towards both the S protein and the ACE2 receptor (Fig. 2). Amarogentin had the highest docking score of $-$149.76 kCal/mol against the S protein. Molecular dynamics simulation revealed that it interacts with the S protein via hydrogen bonding with amino acids Arg765, Cys738, Gln314, Ser735, Thr739, Thr768, and Val736, and with ACE2 receptor via hydrogen bonding with Asp350, Asp382, Asn394, and Tyr385.

An important Ayurvedic method for enrichment of active pharmacological agents from herbs involves preparation of Kadha (decoction) for oral consumption. In a molecular docking study by Maurya and Sharma (2020), the potential for phytoconstituents of common Kadha components to bind to SARS-CoV-2 proteins, ACE2 receptor or pro-inflammatory mediators were investigated (Maurya and Sharma, 2020). The authors reported the findings of 108 phytoconstituents from Withania somnifera, Ocimum tenuiflorum, T. cordifolia, Z. officinale, C. longa, P. nigrum, Syzygium aromaticum, Elettaria cardamomum and Citrus limon. Many of the phytochemicals tested were found to have a strong binding affinity with SARS-CoV-2 proteins. Orientin, withanolide, withanolide B, crategolic acid, ursolic acid, withaferin A, apigenin, eriodictyol, hesperetin, oleanolic acid, stigmasterol and withanone had a high binding affinity with NSP15. Whereas, withanone, withanolide B, withaferin A, withanolide, beta-sitosterol, campesterol, stigmasterol, flavonol glucoside and somniferine A had a high binding affinity to the Nsp9 protein (Fig. 2E). Several phytochemicals, including quercetin, withanone, withanolide and stigmasterol (Fig. 2F), also had high binding affinity to the N protein. Importantly, withaferin A, withanolide B, withanolide, withanone, campesterol, cyclocurcumin, somniferine A, stigmasterol, eriodictyol, isopiperine, oleanolic acid, rhamnetin, orientin, quercetin, piperine and vicenin had high binding affinity for inflammatory mediators cyclooxygenase-2 (COX2), phospholipase A2 (PLA2), NF-ĸB-Inducing Kinase (NIK), and interleukin-1 receptor associated kinase 4 (IRAK-4) (Maurya and Sharma, 2020). Molecular dynamics simulations were performed for M^pro and ACE2 receptors with the above-selected phytoconstituents, and root mean square deviations (RMSD) and root mean square fluctuations (RMSF) plot analysis demonstrated that their interactions are stable with very low variability. As COVID-19 is characterized by high inflammatory response (Mishra et al., 2020), the anti-inflammatory action of the phytoconstituents may be very important for potentially reducing disease symptoms. Moupinamide (Fig. 2), one of the phytoconstituents of Kadha used to relieve symptoms of respiratory influenza like illness, was found to have strong potential to bind stably to both the S protein and the M^pro (Shukla et al., 2021).

Based on the previous findings (discussed above), W. somnifera, T. cordifolia, and O. tenuiflorum are commonly used components for various Ayurvedic formulations. Over one hundred different active phytoconstituents of these herbs were identified as potential M^pro binders and further analyzed for drug-likeness. This has resulted in the identification of six potential phytochemical inhibitors with high stability as evidenced by the RMSD values (withanoside V, somniferine, tinocordiside, vicenin, isorientin 4′-O-glucoside 2’’-Op-hydroxybenzoate and ursolic acid) (Shree et al., 2020). Similarly, nine compounds (linarin, eudesmol, cadinene, geranyl acetate, alpha-thujene, germacrene A, kaempferol-3-O-glucuronide, kaempferide, and baicalin) out of 127 phytoconstituents from Mentha arvensis, Coriandrum sativum, and O. tenuiflorum were found to have potentially high binding affinity towards the catalytic pocket of N protein, with high stability and few fluctuations, as well as favourable drug-likeness (Fig. 2C) (Muthumanickam et al., 2021).

A major limitation of all in silico studies that have thus far been included in this review (Banerjee et al., 2021; Borse et al., 2021; Chikhale et al., 2021; Dhawan et al., 2021; Enmozhi et al., 2021; Kiran et al., 2020; Kumar et al., 2020c; Maurya and Sharma, 2020; Maurya et al., 2020a, 2020b; Mulpuru and Mishra, 2021; Murugesan et al., 2021; Muthumanickam et al., 2021; Parida et al., 2020; Sagar and Kumar, 2021; Shree et al., 2020; Shukla et al., 2021; Srivastava et al., 2020; Tripathi et al., 2021; Upadhyay et al., 2020) is that none have investigated the potential synergistic effects. Given that whole herbs are used for Ayurvedic formulations, it is not clear whether the activities attributed to individual phytoconstituents would be functional in practice. Therefore, further laboratory studies using whole herb extracts, and observational clinical studies in cohorts using Ayurvedic formulations are needed to investigate the in silico predictive studies for potential therapeutic properties.

To the best of our knowledge, only one study included in the present review used a disease association model and attempted to predict synergy among component molecules to contribute to the immunomodulatory potential of the whole extract (Banerjee et al., 2021). The 12 phytoconstituents identified in an ethanolic extract of A. paniculata were further analysed in silico by network pharmacology methods. The gene-disease network analysis identified several targets that were associated with viral infections and immunodeficiency. Andrographolide and andrographodin A were predicted to interact with important immune markers (toll like receptors) and to modulate the PI3K-AKT pathway that is implicated in coronavirus infection (Kindrachuk et al., 2015). The authors conclude that there is a synergistic action between phytoconstituents that may affect an anti-inflammatory response.

In summary, in silico studies clearly show that phytoconstituents of commonly used Ayurvedic herbal formulations have potential to inhibit SARS-CoV-2 infection and COVID-19 disease. As most formulations are commonly delivered orally, it is not clear if, and how, the bioactive compounds reach the respiratory system, thus the question whether some of the interactions with host factors take place in circulation and hence reduce systemic disease markers.

Pre-clinical investigations

Based on our searches, only five studies (Balkrishna et al., 2021b, 2021c, 2020; Gheware et al., 2021a; Upadhyay et al., 2020) have tested the ability of selected bioactive phytoconstituents of Ayurvedic herbs to directly bind and/or inhibit the function of SARS-CoV-2 proteins. Terminalia chebula is the major constituent of the Ayurvedic formulation known as Triphala and it has been reported to be beneficial in disease caused by herpes simplex virus-2 (Kesharwani et al., 2017) and Influenza A virus (Li et al., 2020). The aqueous extract of T. chebula was shown to be effective in inhibiting the proteolytic activity of SARS-CoV-2 3CL^pro in an in vitro protease assay based on cleavage of casein (Upadhyay et al., 2020).

Withanone, a steroidal lactone, highlighted repeatedly as a potential inhibitor of ACE2-S protein interaction in molecular docking studies, was found to inhibit the interaction of the ACE2 receptor with the RBD of S protein in vitro, in a dose dependent fashion (Balkrishna et al., 2021c). Importantly, a herbal extract of W. somnifera enriched with withanone was able to ameliorate pathological symptoms in a zebrafish xenotransplant model that used the S protein as a marker for SARS-CoV-2 infection. The same group also investigated T. cordifolia (Balkrishna et al., 2021b) and Swasari Vati (Balkrishna et al., 2020) as potential treatment options for COVID-19 using the zebrafish xenotransplant model. Swasari Vati is a calcium rich Ayurvedic mixture of 16 herbs or their extracts, processed into a tablet containing three excipients and is commonly prescribed for chronic cough, common cold and asthma. Treatment with Swasari Vati led to the complete recovery of the zebrafish as measured by renal degeneration, necrosis, and survival. Importantly, Swasari Vati treatment showed progressive recovery of immune cell infiltration with very few pro-inflammatory infiltrates, suggesting its effectiveness in reducing the inflammatory damage caused by SARS-CoV-2 spike protein (Balkrishna et al., 2020). In a similar study, T. cordifolia extract in the form of orally delivered powdered tablet, was also found to be effective in reversing the pathological symptoms in the zebrafish model (Balkrishna et al., 2021b).

Only one group investigated the effect of an Ayurvedic herbal extract in a mouse model of COVID-19 disease (Gheware et al., 2021a). The authors have previously shown that an extract of Justicia adhatoda (one of the component herbs in KSK, see above) has an anti-hypoxic property and can reduce severe airway inflammation induced by an augmented hypoxic response in a mouse model of treatment-resistant asthma (Gheware et al., 2021b). The group extended their investigations to show that J. adhatoda extract can inhibit SARS-CoV-2 replication in cell culture and reverse the pulmonary fibrosis in a bleomycin mice model where treatment with the extract resulted in reduced pro-inflammatory mediators and markers of hypoxia. The authors concluded that J. adhatoda extract may be a potential candidate for development of anti-SARS-CoV-2 treatment.

Clinical trials

A number of clinical trials are currently ongoing or have been completed on the use of Ayurvedic formulations in mild and moderate COVID-19 disease. The clinical trials are mostly observational studies on cohorts of patients who are using Ayurvedic formulations as part of their treatment regime. In this context, the Indian Government has set up guidelines for the clinical management of COVID-19 patients based on Yoga and Ayurveda (Government of India, 2020) that includes preventative measures for general use in the community.

There were 51 completed clinical trials on the use of Ayurvedic formulations to prevent or treat COVID-19 registered at ClinicalTrials.gov (https://clinicaltrials.gov) and Clinical Trial Registry-India (http://ctri.nic.in/Clinicaltrials/login.php) as of 20th March 2022. The protocol details of all completed clinical trials on different Ayurvedic formulations are provided in Table 2 . The majority are small, single-center trials undertaken in different jurisdictions in India in SARS-CoV-2 positive subjects with asymptomatic or mild disease, comparing the Ayurvedic treatments with standard care. The outcomes of these studies varied considerably between the studies; however, trial outcome data was only available for 17 completed trials and these are discussed below.

Table 2.

List of completed clinical studies with Ayurvedic formulations.

Formulation/ Compound

Study design

clinical phase

Intervention details

Outcome measures

Sample size

clinical study identifier

Dabur™ Chyawanprash (DCP)

Randomised, Parallel-Group Trial

N/A

Adults (13 −70 years): One teaspoonful (approx. 12 gm of Chyawanprash) twice daily, followed by milk Children (5–12 years): Half teaspoonful (approx. 6 gm of Chyawanprash) twice daily, followed by milk

Comparative assessment of the incidence of COVID-19 in subjects who take DCP and those who do not take it for three months (90 days)

600

CTRI/2020/05/024,981

AYUSH 64

Randomised, Parallel Group, Active Controlled Trial

Phase 2/ Phase 3

Capsules (500 mg each) thrice a day after food

Early recovery from COVID-19 infection

80

CTRI/2020/05/025,214

Kabasura Kudineer

Randomised, Parallel-Group Trial

Phase 1/ 2

Kabasura Kudineer 60 ml twice a day for 14 days

Reduction in Viral load, clinical recovery

50

CTRI2020/05/025,215

Ashwagandha,

Randomised, Parallel-Group, Placebo-Controlled Trial

N/A

500 mg twice a day after Breakfast/ Dinner

Reduction in viral load

120

CTRI/2020/05/025,273

Giloy,

1000 mg twice a day after Breakfast/ Dinner

Tulsi

500 mg twice a day after Breakfast/Dinner

Anu Taila

4 drops twice a day

Swasari Ras

2 gm twice a day before Breakfast/ Dinner

Chyawanprash

Randomised, Parallel-Group Trial

Phase 3

Twice a day - on an empty stomach in the morning at least 1 h before breakfast and in the evening two hours after dinner

Percentage of participants with SARS- Cov-2 positivity

200

CTRI/2020/05/025,275

Sanshamani Vati, Nagaradi kwath,

Single Arm Trial

Phase 3

1 gm twice a day with 50 ml kwath decoction

Time and number of patients transitioning from an asymptomatic to a symptomatic state

50

CTRI/2020/05/025,276

Amalaki Churna,

3 gm with water once a day at 5 pm, for 14 days

Golden Milk

Once daily, 9 pm, for 14 days

Tab PINAK

Single Arm Trial

Phase 2

Moderate to severe illness: 4 times a day for five days; Mild: 3 times a day for five days.

Early recovery and reduced mortality

30

CTRI/2020/05/025,326

AYUSH-64

Single Arm Trial

Phase 3

2 Tablets (500 mg) thrice daily

Clinical recovery

40

CTRI/2020/05/025,335

AYUSH −64

Single Arm Trial

Phase 2/ Phase 3

2 Tablets (500 mg each) thrice a day after food

Early recovery and changes in liver enzymes, Renal functions

40

CTRI/2020/05/025,338

Guduchi Ghan Vati

Non-randomised, Multiple Arm Trial

N/A

500 mg two times a day for 30 days.

Comparative assessment of incidence of infection in clinically stable participants in the community who have already identified at least one confirmed case with the standard prophylaxis control arm

30,000

CTRI/2020/05/025,385

Curcumin with black pepper

Randomised, Parallel-Group Trial

N/A

525 mg. Two to four tablets a day.

Variations in d-Dimer, CRP, LDH, CBC, Ferritin, Troponin, cardiac myoglobin, PT INR, clinical improvement.

50

CTRI/2020/05/025,482

CLEVIRA

Randomised, Parallel-Group Trial

Phase 3 / Phase 4

Tablet twice daily for 14 days

Recovery and reduction of viral load

100

CTRI/2020/05/025,483

Ashwagandha (Shakti)

Single Arm Trial

Phase 3/ Phase 4

5 drops three times a day

Early clinical recovery

50

CTRI/2020/06/025,592

Amruth,

1 tablet twice a day

Turmeric,

1 tablet twice a day

Tulsi

10 drops thrice a day

Shunthi

Randomised, Parallel Group, Active Controlled Trial

Phase 2

10 day treatment 2 gm twice daily

To minimize the likelihood of disease progression in terms of severity. Reduction of viral load and clinical recovery

120

CTRI/2020/06/025,800

Rasona

1 gm once daily

Vyaghryadi Kashaya

50 ml twice daily

Samshamani Vati

500 mg twice daily

Agnikumara Rasa

125 mg twice daily

Septilin and Bresol

Randomised, Parallel Group, Active Controlled Trial

Phase 2/ Phase 3

One tablet twice daily from day one upto14 days.

Early recovery and changes in liver enzymes, Renal functions To minimize the likelihood of disease progression in terms of severity.

40

CTRI/2020/06/025,801

AYUSH-64

Randomised, Parallel-Group Trial

Phase 2

2 Capsules of 500 mg thrice daily for 14 days

Recovery.

200

CTRI/2020/06/025,855

Kabasura Kudineer

Non-randomised, Multiple Arm Trial

Phase 2

60 ml twice a day, before food.

Resolution of Symptoms and recovery

200

CTRI/2020/06/025,856

Vasantha kusumakaram

1 tablet twice a day, after food.

Thippili Rasayanam

2 g twice a day, after food.

Adathodai Manapagu

15 ml twice a day with 30 ml lukewarm water, after food for 14 days

Arogya Kashayam-20

Randomised, Parallel Group, Active Controlled Trial

Phase 2

100 ml Twice a day for ten days

Check the progression of the disease

100

CTRI/2020/06/026,221

Dashamula Kwatha, Pathyadi Kwatha, Trikatu Churna

Randomised, Parallel Group, Active Controlled Trial

N/A

Decoction of 20 ml each of the Kwathas and 2 gm Trikatu Churna twice a day on an empty stomach

Clinical recovery

25

CTRI/2020/07/026,433

Sansamani Vati,

500 mg two tablets twice a day after meal,

AYUSH-64,

Two tablets twice a day after a meal,

Yastimadhu Ghanavati

One chewable tablet (500 mg) six times a day every two hours in a daytime

Immusante and Guduchi

Randomised, Parallel Group, Active Controlled Trial

Phase 3

Each tablet: 1 tablet twice daily for 30 days

Improvement in the immune status based on the adapted Immune status

100

CTRI/2020/07/026,579

Surasadi Kadha,

Single Arm Trial

Phase 2/ Phase 3

50 ml twice a day for seven days

Clinical recovery

70

CTRI/2020/07/026,601

ViroNil,

Capsule (500 mg) daily for seven days

Bilvadi

Capsule twice a day for seven days

SSV Formulation

Randomised, Parallel Group, Active Controlled Trial

Phase 3

Tablet of (500 mg), twice a day immediately after meals for ten days

Reduction of clinical symptoms and disease severity

200

CTRI/2020/07/026,839

Guduchi Ghan vati

Randomised, Parallel Group, Active Controlled Trial

N/A

Two capsules/tablet (250 mg each) twice a day after food

Early recovery.

30

CTRI/2020/07/026,840

Kabasura Kudineer, Nilavembu Kudineer

Double Blinded, Three arm, Single center, Placebo Controlled, Randomized Controlled Trial

N/A

Placebo or NVK or KSK, 60 ml Morning and Night after Food, along with standard Allopathy Treatment for 10 days.

Reduction in viral load

125

CTRI/2020/08/027,286

Immunofree

Randomised, Parallel-Group Trial

Phase 3/ Phase 4

Two tablets 500 mg thrice a day for ten days

Early recovery.

100

CTRI/2020/08/026,957

Reginmune

One capsule 750 mg twice a day for ten days

Nochi Kudineer Chooranam,

Randomised, Parallel Group, Active Controlled Trial

Phase 2

Decoction – Two times daily before 30 min of meals for seven days

Reduction of viral load and clinical recovery

100

CTRI/2020/08/026,999

Mahasudarsan Chooranam,

5 gm – Two times daily after meals for seven days with warm water/ Honey.

Maldevi Chendooram,

100 mg. Two Times daily, after meals for seven days with honey.

Adathodai Manapagu,

10 ml- Morning and Evening for seven days.

Omatheeneeer

10 ml –Twice daily with water after meals for seven days.

Shakthi,

N/A

Phase 3/ Phase 4

5 drops, three times a day

Changes in anti-oxidant biomarkers (Superoxide dismutase, Catalase, MalondialdehydeGlutathione) and Immune biomarkers (IFN-α, IFN- β)

100

CTRI/2020/08/027,009

Amruth,

1 tablet, two times a day

Turmeric Plus,

1 tablet, two times a day

Tulsi Arka

10 drops, three times a day

Ashwagandha Tablet,

Randomised, Parallel Group, Active Controlled Trial

Phase 2/ Phase 3

2 Tablets 250 mg each, twice a day, 2 hrs after food

Early recovery

60

CTRI/2020/08/027,224

Shunti Capsule

2 capsules 500 mg each, twice a day at least 30 min after food

T-AYU-HM Premium

Single Arm Trial

Phase 2

600 mg twice a day for 21 days

Changes in clinical symptoms

30

CTRI/2020/08/027,477

Kabasura Kudineer,

Single Arm Trial

Decoction – Two times daily before 30 min of meals for seven days

Reduction in viral load and clinical symptoms

20

CTRI/2020/08/027,490

Amukkara,

2 tablets - Three times daily after meals for seven days

Thaleesadhivadagam,

2 Chewable tablets – Three times daily after meals for seven days

Brammanandhabairavam,

1 pill - Two times daily after meals for seven days

Adathodaimanapagu

10 ml –Twice daily with warm water after meals for seven days

Kabasura Kudineer

Single Arm Trial

Phase 2

Decoction – Twice daily 30 min before meals for 7 days

Reduction in viral load and clinical symptoms

20

CTRI/2020/08/027,491

Amukkara Chooranam Mathirai

Two tablets - Thrice daily after meals for 7 days

Thaleesadhivadagam

Two tablets – Thrice daily after meals for 7 days

Brammanandhabairavam

One pill - Twice daily after meals for 7 days

Adathodaimanapagu

10 ml –Twice daily with warm water after meals for 7 days

Elaeocarpus sylvestris var. ellipticus extract

Randomised, Parallel-Group, Placebo-Controlled Trial

Phase 2

480 mg per day orally for ten days

Early, changes in mental health, and changes in levels of prostaglandin E2, TNF α, and IL-6

60

CTRI/2020/09/027,775

Tulsi,

Randomised, Parallel-Group Trial

Phase 2/ Phase 3

1 tablet two times a day for 28 days,

Early recovery

72

CTRI/2020/09/027,914

Giloy ki Ghanvati,

1 tablet two times a day for 28 days

Kalmegh,

1 tablet two times a day for 28 days

Dabur™ Chyawanprash

1 teaspoonful (Approx 10–12 gs) two times a day for 28 days

AyurCoro-3

Single Arm Trial

N/A

10 ml of liquid, three times a day for one day, repeat every 15 days for three months

Clinical recovery

120

CTRI/2020/10/028,324

AyurCoro-3

Randomised, Parallel-Group Trial

Phase 3/ Phase 4

10 ml three times a day for three days. Medication for a day

Clinical recovery

500

CTRI/2020/10/028,333

Bilwadi Yog,

Randomised, Parallel Group, Active Controlled Trial

Phase 3

1 gm twice a day

Early recovery from COVID-19 infection and reduction in viral load

380

CTRI/2020/10/028,437

Kantakaryavaleha

3 gm twice a day

*Shadangodak

40 ml twice a day

NIFAy.C-19 (CONTAZAP)

Randomised, Parallel-Group Trial

Phase 3/ Phase 4

640 mg- 2 Capsules, twice daily after meal.

Clinical recovery

120

CTRI/2021/01/030,169

Jeevaneeyam, Ojovardhini, Amrutha Sanjeevini

Non-randomised, Active Controlled Trial

Phase 3/ Phase 4

Twice a day after meal for 14 days

Reduction in clinical symptoms and early recovery

60

CTRI/2021/02/031,353

Kabasura Kudineer

Randomised Parallel

Phase 4

Two tablets a day thrice before food

Early clincal recovery

200

CTRI/2021/04/032,755

AEV01 (Kutki/ Picrorhizakurroa)

Randomised, Parallel-Group, Placebo-Controlled Trial

Phase 3

Thrice daily orally after food for 30 days

Alleviation of COVID-19 symptoms.

70

CTRI/2021/04/032,804

Zandu™ Chyawanprash,

Randomised, Parallel-Group Trial

Phase 2/ Phase 3

10–12 gm twice daily for 8 weeks

Clinical recovery. Comparative assessment of post-clinical recovery based on signs and symptoms.

60

CTRI/2021/01/030,733

Zandu™ Pure Honey,

1 teaspoonful twice daily for 8 weeks

*Trishun,

1 tablet twice daily for 2 weeks

Immuzan

2 tablets twice daily for 8 weeks

CIM-MEG19

Non-randomised, Active Controlled Trial

Phase 2

2 Tablets twice daily after meal for 21 days

Recovery and improvement in WHO-QOL

80

CTRI/2021/05/033,472

CIM-MEG19

Randomised, Parallel Group, Active Controlled Trial

Phase 2

Two tablets two times a day after meal

Changes in time to 2-point improvement (from time of enrolment) on the WHO ordinal scale

80

CTRI/2021/05/033,543

NOQ19

Randomised, Parallel Group-Placebo Controlled Trial

Phase 4

Two tablets– Thrice daily after meals for 3 months

Prevention of COVID-19 and symptom severity in infected cases

5000

CTRI/2021/07/034,606

NOQ19

Randomised, Parallel Group-Placebo Controlled Trial

NA

Two tablets– Thrice daily for 14 days

Duration of hospital stay, resolution of symptoms, and early clinical recovery

100

CTRI/2022/01/039,370

Amukkura chooranam

NA

Phase 2

5 gs, twice daily for 15 days

Prevention or reduction of post COVID-19 complications

1409

CTRI/2021/07/035,028

NOQ19

Randomised, Parallel Group-Placebo Controlled Trial

Phase 2

Two tablets– Thrice daily for 10 days

Early clinical recovery and symptoms

155

CTRI/2021/08/036,025

NOQ19

Randomised, Parallel Group-Placebo Controlled Trial

Phase 3/ 4

Two tablets-Three times a day for 14 days

Reduction in Viral load, clinical recovery

40

CTRI2021/10/037,423

Guduchi Ghan Vati

Retrospective study

N/A

Two tablets (500 mg each) twice daily were given orally after meal for 28 days

Early recovery and reduction in viral load

91

NCT04480398

Guduchi Ghan Vati

Single-arm study

N/A

Two tablets (1000 mg) twice daily for two weeks

Early recovery and reduction in viral load

46

NCT04542876

Shanshamani Vati plus (Guduchi and Pipli)

Single Group Assignment

N/A

Shanshamani Vati Plus was given twice daily

Alleviation of symptoms

26

NCT04621903

Ashwagandha,

Community-Based Participatory Research

N/A

250 mg – 5 g based on age, weight and severity of symptoms

Early recovery

28

NCT04716647

Giloy

500 mg – 1 g based on age, weight and severity of symptoms

Tulsi

500 mg–1 g based on age, weight and severity of symptoms

Guduchi Ghanvati

Non-Randomized

N/A

500 mg of Samshamani vati or Giloy Ghanavati twice daily

Clinical recovery

216

NCT04920773

Various formulations containing T. cordifolia, A. paniculata, W. somnifera, O. tenuiflorum, Z. officinale, T. chebula, C. longa, and E. officinalis have shown positive results in prophylaxis and treatment of COVID-19. Several clinical studies have been reported on the use of KSK, with reduction in SARS-CoV-2 viral load and faster recovery of COVID-19 patients (CTRI2020/05/025,215, CTRI/2020/08/027,286), (Natarajan et al., 2020, 2021; Srivastava et al., 2021a, 2021b). Patients in the placebo group had a significantly longer stay in the hospital (mean ± SD = 8.4 ± 2.0 days) as compared to patients receiving KSK (mean ± SD = 4.2 ± 1.5 days; Kruskal-Wallis test, P = 0.0001) (Srivastava et al., 2021b). Further study showed that patients given KSK as a decoction had a larger reduction in viral load as compared to the control group of patients who received vitamin C and zinc tablets (no statistical analysis provided) (Natarajan et al., 2021).

In one clinical trial (CTRI/2020/06/025,856), several Ayurvedic formulations were evaluated in combination with a ‘standard treatment’ which consisted of five pharmaceuticals and 2 nutraceuticals. It should be noted that none of the seven drugs have been shown to have any direct effect on SARS-CoV-2 or COVID-19 although some have generalised effects that may be beneficial (Siemieniuk et al., 2020). The pharmaceuticals included were Hydroxychloroquine, Ivermectin, azithromycin, paracetamol, Omez as well as Vitamin C and zinc. The Ayurvedic add on treatment included KSK, Adathodai manapagu, Vasantha kusumakaram mathirai and Thippili rasayanam; all of which are used in the community for relief of respiratory symptoms. The authors reported improved recovery of those given the Ayurvedic formulations as add-on to the ‘standard treatment’ (Chitra et al., 2021), with a reduction in the average number of days taken for symptoms to improve following treatment (3.21 with add-on vs 5.13 with only standard treatment (P < 0.001)). This was not surprising as most of the components in the ‘standard treatment’ have not been shown to have a direct effect on COVID-19 clinical progression (Bartoszko et al., 2021; Siemieniuk et al., 2021).

A trial by Thakar et al. (CTRI/2020/07/026,433) compared the effect of ‘standard treatment’ (Vitamin C, azithromycin, and paracetamol) with an Ayurvedic add-on treatment (Thakar et al., 2021). The Ayurvedic add-on treatment consisted of the State Government recommended combination of Dashamula and Pathyadi kwatha, Trikatu churna, Guduchi ghan vati, AYUSH-64 and Yastimadhu ghanvati, all of which are polyherbals used primarily in respiratory and influenza like illness. Dashamula, alone and in combination with aspirin has previously shown to have anti-inflammatory, analgesic, and anti-platelet effects comparable to aspirin alone (Parekar et al., 2015). Trikatu powder contains black and long pepper and probably augments the metabolic process by improved absorption of nutrients through the action of the phytoconstituent piperine (Zhang et al., 2021). Given its predicted ability to bind to the S protein (Maurya et al., 2020b), piperine may also have a role in inhibiting SARS-CoV-2 infection. Yastimadhu (G. glabra) or licorice is used widely in both Ayurveda and Traditional Chinese Medicine and shown to have antimicrobial activity (Wang et al., 2015). The AYUSH-64 is a polyherbal formulation with its basis in Ayurvedic herbs and has previously been shown to be effective in malaria (Willcox, 2011) and in influenza like illness (Gundeti et al., 2020). In this study participants in the ‘add-on treatment’ group showed similar outcomes to CTRI/2020/06/025,856 clinical trial with shortened duration of symptomatic phase of the infection compared to those on standard treatment alone (mean ± SD = 3.66 ± 1.55 compared to 5.34 ± 3.35 days, p < 0.001); no adverse reactions or drug interactions were observed. There was no difference in progression to symptomatic disease (27.6% compared to 24.6%).

A retrospective, open label clinical study by Balkrishna et al. (2021a) found that Ayurvedic treatment alone led to shorter time to recovery of COVID-19 patients, when compared to patients receiving the Ayurvedic treatment as an add-on with standard drug treatment (azithromycin with Vitamin-C and anti-histamines (not specified) and acetaminophen as prescribed) (Balkrishna et al., 2021a). The Ayurvedic treatment consisted of the polyherbal formulations Swasari Ras, Tulsi Ghanvati and Anu Taila, and herbal extracts of T. cordifolia and W. somnifera. A trial by Devpura et al. (2021) in a geographically distant region of India (CTRI/2020/05/025,273) compared the anti-COVID-19 efficacy of the same Ayurvedic treatment with placebo (Devpura et al., 2021) and found that treatment was better than placebo in reducing time to a negative diagnostic test. Several phytoconstituents of both T. cordifolia and W. somnifera are predicted to bind to SARS-CoV-2 proteins S and M^pro and the ACE2 receptor in molecular docking studies (refer to section above) and oral T. cordifolia treatment reversed pathology in a zebrafish xenotransplant model of COVID-19 (Balkrishna et al., 2021b). Interestingly, totality of evidence from in silico studies, animal models and clinical trials strongly suggest a multipronged mechanism underlying the observed effects of T. cordifolia on COVID-19.

A trial by Rais et al. (CTRI/2020/06/025,800) evaluated the efficacy of Vyaghryadi kashaya and Samshamani vati or Shunthi churna and Rasona kalka relative to ‘standard treatment’ of paracetamol with Vitamin C (Rais et al., 2021) in SARS-CoV-2 positive subjects with very mild or no clinical symptoms. Participants on either Ayurvedic treatment had a shorter period to recovery. 98–100% of participants on the Ayurvedic ‘add-on’ treatments tested negative for COVID-19 on day 7, compared to 68% in the ‘standard treatment’ group (p < 0.001). There was some variation in the efficacy of the two Ayurvedic treatments in relation to specific clinical symptoms of fever, sore throat, cough, and loss of taste.

A treatment regime of T. cordifolia, O. tenuiflorum, A. paniculata tablets and Chyawanprash, an Ayurvedic supplement, as an add-on to (unspecified) ‘standard of care’ was evaluated for efficacy in mild to moderate COVID-19 hospitalized patients (CTRI/2020/09/027,914). The authors found that participants given the add-on treatment with the ‘standard of care’ had a shorter period to recovery (mean ± SD = 10.77 ± 3.24 days), compared to those on ‘standard of care’ alone (16.30 ± 5.93; p < 0.001)(Gupta et al., 2021).

Two separate retrospective clinical trials studied the efficacy of T. cordifolia extract in confirmed asymptomatic COVID-19 patients (NCT04480398) compared to ‘standard of care’ (isolation and clinical monitoring). Although no results have been posted on the Clinical Trials site, preliminary findings are included in a preprint article (Kumar et al., 2020b). The treatment group remained asymptomatic and cleared the virus in a shorter period relative to the group on ‘standard of care’. A companion single arm study of the efficacy of T. cordifolia extract with no control group was also conducted by the same group (NCT04542876) (Kumar et al., 2020a) on a cohort of asymptomatic SARS-CoV-2 positive subjects. Of the subjects who completed the study, none developed any symptoms and 95% returned a negative diagnostic test on day 7.

A pilot community-based participatory research study (Back to Roots, NCT04716647) investigated the safety and efficacy of T. cordifolia and P. longum extracts in patients in Leicester, UK, with mild to moderate COVID-19. The primary measures were clinical improvement and deterioration in clinical status to severe/critical. The study outcomes are available as a MedRxiv preprint and showed no participants were hospitalised for medical or oxygen requirements and none developed breathing difficulties with average time to recovery being 4.85 (±.1.8) days compared to 13.5.±.6.4 days in the control group (p < 0.0001) (Kulkarni et al., 2021).

Curcumin, and its bioactive formulations have gained significant attention in recent years for the treatment of inflammatory diseases. One randomized clinical trial (CTRI/2020/05/025,482) investigated the usefulness of Bioperine®, containing curcumin with piperine, as adjuvant therapy for COVID-19 patients (Pawar et al., 2021). In line with the other trials discussed in this review, the authors found that Ayurvedic treatment resulted in early symptomatic recovery compared to the control group who received probiotics. This is the only trial we have found that included patients with mild, moderate and severe disease.

A randomized, controlled, multi-center clinical trial compared W. somnifera extract with hydroxychloroquine for efficacy in pre-exposure prophylaxis (CTRI/2020/08/027,163). The interim results (Chopra et al., 2021) showed that W. somnifera extract was no worse than hydroxychloroquine; the latter had been recommended for such use by the Indian Council for Medical Research. One participant in the W. somnifera group and three in the hydroxychloroquine group contracted COVID-19 during the initial eight weeks.

A recent randomized, placebo controlled, single center clinical trial (CTRI/2021/10/037,423) investigated the efficacy of the polyherbal NOQ19 on the rate of recovery and clinical improvement among moderate to severe COVID-19 patients who were not on a ventilator or in intensive care unit. The outcomes of the trial are available as a preprint on ResearchSquare (Arun et al., 2021). Participants enrolled in the study received either NOQ19 or placebo, along with the ‘standard of care’ which included Doxycycline, Azithromycin, Ivermectin, Vitamin C, Zinc and paracetamol. Hospitalised participants also received supportive care, e.g. intravenous fluids and oxygen therapy, as determined by the overseeing physician. There were more participants with ‘severe’ disease in the NOQ19 arm (59%) compared to the placebo arm (22%) and all enrolled participants were monitored for 14 days. There was no statistically significant difference in recovery times between the two arms as a whole. However, a significant increase in the number of participants returning a negative test for COVID-19 on day 7 was observed in the NOQ19 arm when ‘moderate’ and ‘severe’ participants were considered separately.

The discussion of the limited trials data available is strongly suggestive of some advantage in the use of specific Ayurvedic formulations in the clinical management of COVID-19, with no adverse events associated with such treatment. All treatments used in clinical trials were those used commonly for respiratory indications, and hence did not present a significant risk. As Ayurvedic treatments are well accepted in the global Indian community, and the Government of India has recommended specific Ayurvedic treatments in its COVID-19 management guidelines, the trials have been conducted primarily within that population group.

Conclusions

The emergence of SARS-CoV-2 and the resulting COVID-19 global pandemic has seen a resurgence of research into the antiviral efficacy of Ayurvedic herbal formulations. This is primarily due to the current lack of effective, safe, widely available antiviral treatments in addition to the herbal treatments being relatively cheap and easy to transport without requirement for specific storage conditions. Furthermore, the widespread use of Ayurvedic formulations in India presented an opportunity for these treatments to be examined using well designed and controlled clinical trials.

In the current review article, the evaluation of in silico, in vitro, in vivo and clinical evidence for use of Ayurvedic formulations and their herbal constituents is presented:

• aIn silico techniques were reported in 20 peer review publications. It appears that a variety of different Ayurvedic formulations exhibit antiviral activities as ACE2 and/or 3CL^pro inhibitors. Despite relatively limited literature describing the RNA polymerase inhibitions, these formulations may be considered as a platform for development of future antiviral treatments.
• bThe findings of pre-clinical animal models were reported in only five studies where Ayurvedic herbs were found to inhibit the proteolytic activity of 3CL^pro of SARS-CoV-2 proteins.
• cOver 50 clinical trials were completed where Ayurvedic formulations were used to prevent or treat COVID-19 symptoms. A majority of the trials were relatively small in size (less than 30 participants), single-centered, and in participants who were asymptomatic or had mild self-reported symptoms.

Many of the studies in this review have focussed on in silico investigations and the potential of individual phytoconstituents to bind to SARS-CoV-2 proteins. As these formulations are almost always taken as herbal extracts, these studies, although useful in themselves, provide relatively limited understanding of the clinical mechanisms that result in reduced period to recovery observed in clinical trials. Clearly, use of Ayurvedic formulations is warranted in all levels of COVID-19 disease as it is, at least, as effective as some of the other currently available treatments and may be rather beneficial in shortening period to recovery. Furthermore, use of Ayurvedic formulations as an “add-on” treatment to the already established medical interventions can also produce beneficial outcomes in individuals at different levels of SARS-CoV-2 infection (asymptomatic and mildly symptomatic).

Limitations of this literature review include its narrative design and that the studies included are reporting on observational findings with relatively limited descriptions of mechanisms of action. Nevertheless, the findings of this literature review also highlight the possibility of applying knowledge gained from traditional medicine with modern medicine approaches across patient populations in addition to those with COVID-19.

Funding

None

CRediT authorship contribution statement

Anees Ahmed Mahaboob Ali: Investigation, Writing – original draft, Writing – review & editing, Formal analysis. Andrea Bugarcic: Writing – review & editing. Nenad Naumovski: Writing – review & editing, Visualization. Reena Ghildyal: Conceptualization, Writing – original draft, Writing – review & editing, Validation, Visualization.

Declaration of Competing Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.